OVERVIEW

Optimizing Antithrombotic Therapy in Patients With Atrial Fibrillation Who Have an Acute Coronary Syndrome or Have Undergone PCI: New Data, New Directions is organized by Paradigm Medical Communications, LLC.

Release Date: December 18, 2019
Expiration Date: December 18, 2020

Accreditation:
Physician Credit Designation Statement:
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation and Designation Statement:
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.5 hours (0.15 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

PA Continuing Education:
PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Learning Objectives:
Upon proper completion of this activity, participants should be better able to:
• Interpret key clinical findings from recent trials related to antithrombotic management of patients with AF who have an ACS or have undergone PCI
• Choose optimal antithrombotic treatment for patients with AF who have an ACS or have undergone PCI based on the latest evidence, and with consideration of stroke and bleeding risks
• Individualize the duration of antithrombotic therapy in patients with AF who have an ACS or have undergone PCI based on patient risk factors

Additional details will be posted as soon as information is available.